Authors/Disclosures
|
Hussam Shaker, MD
(C&RMEP)
|
Dr. Shaker has nothing to disclose. |
|
Mohammad Haykal, MD
(Beaumont Health Neurology)
|
No disclosure on file |
|
David E. Burdette, MD
(Corewell Health)
|
Dr. Burdette has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Catalyst. Dr. Burdette has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life pharmaceuticals. Dr. Burdette has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for NeuroPace. Dr. Burdette has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Burdette has received research support from Longboard. The institution of Dr. Burdette has received research support from NeuroPace. |
|
Bassel Raad, MD
(Advent Health)
|
No disclosure on file |
|
Adam Brickman, PhD
|
Adam Brickman, PhD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for IQVIA. Adam Brickman, PhD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cognito Therapeutics. Adam Brickman, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Illinois. Adam Brickman, PhD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NovoNordisk. Adam Brickman, PhD has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer's & Dementia. Adam Brickman, PhD has stock in Tau Biosciences. Adam Brickman, PhD has stock in CogniScreen. |